{
  "title": "Aflibercept",
  "content-preview": "Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals.\nIt is an inhibitor of vascular endothelial growth factor (VEGF).\n\n\n== Medical uses ==\nAflibercept (Eylea)",
  "url": "https://en.wikipedia.org/wiki/Aflibercept",
  "pageid": 17545444,
  "title-terms": {
    "aflibercept": 1
  },
  "content-terms": {
    "aflibercept": 27,
    "sold": 1,
    "brand": 1,
    "names": 1,
    "eylea": 10,
    "zaltrap": 8,
    "medication": 1,
    "used": 3,
    "treat": 2,
    "wet": 9,
    "macular": 18,
    "degeneration": 9,
    "metastatic": 7,
    "colorectal": 5,
    "cancer": 14,
    "developed": 1,
    "regeneron": 5,
    "pharmaceuticals": 1,
    "inhibitor": 1,
    "vascular": 3,
    "endothelial": 3,
    "growth": 5,
    "factor": 4,
    "vegf": 3,
    "medical": 6,
    "uses": 1,
    "indicated": 2,
    "treatment": 19,
    "people": 5,
    "neovascular": 4,
    "agerelated": 4,
    "edema": 9,
    "following": 3,
    "retinal": 3,
    "vein": 3,
    "occlusion": 3,
    "diabetic": 9,
    "retinopathy": 5,
    "prematurity": 2,
    "combination": 3,
    "fluorouracil": 2,
    "leucovorin": 2,
    "irinotecan": 4,
    "known": 1,
    "folfiri": 1,
    "resistant": 2,
    "progressed": 2,
    "oxaliplatincontaining": 1,
    "regimen": 3,
    "administered": 1,
    "intravitreal": 1,
    "injection": 2,
    "eye": 8,
    "given": 1,
    "intravenously": 1,
    "july": 1,
    "2014": 1,
    "approved": 12,
    "visual": 8,
    "impairment": 7,
    "due": 7,
    "may": 2,
    "2019": 1,
    "us": 4,
    "fda": 6,
    "expanded": 1,
    "indication": 1,
    "include": 2,
    "stages": 1,
    "february": 3,
    "2023": 4,
    "contraindications": 2,
    "contraindicated": 1,
    "infections": 1,
    "active": 2,
    "inflammations": 1,
    "near": 1,
    "adverse": 3,
    "effects": 4,
    "common": 2,
    "formulation": 2,
    "conjunctival": 1,
    "hemorrhage": 1,
    "pain": 2,
    "cataract": 1,
    "vitreous": 1,
    "detachment": 1,
    "floaters": 1,
    "ocular": 1,
    "hypertension": 2,
    "typical": 1,
    "anticancer": 1,
    "drugs": 4,
    "reduced": 1,
    "blood": 5,
    "cell": 2,
    "count": 1,
    "leukopenia": 1,
    "neutropenia": 1,
    "thrombocytopenia": 1,
    "gastrointestinal": 1,
    "disorders": 1,
    "like": 2,
    "diarrhea": 1,
    "abdominal": 1,
    "fatigue": 1,
    "another": 1,
    "effect": 1,
    "increased": 1,
    "pressure": 1,
    "interactions": 2,
    "described": 1,
    "either": 1,
    "mechanism": 1,
    "action": 1,
    "abnormal": 1,
    "vessels": 2,
    "grow": 1,
    "choriocapillaris": 2,
    "layer": 1,
    "capillaries": 1,
    "leading": 1,
    "protein": 2,
    "leakage": 1,
    "macula": 1,
    "binds": 1,
    "circulating": 1,
    "vegfs": 1,
    "acts": 1,
    "trap": 1,
    "thereby": 1,
    "inhibits": 1,
    "activity": 1,
    "subtypes": 1,
    "vegfa": 1,
    "vegfb": 1,
    "well": 1,
    "placental": 1,
    "pgf": 1,
    "inhibiting": 1,
    "new": 2,
    "tumour": 1,
    "respectively": 1,
    "aim": 1,
    "speak": 1,
    "starve": 1,
    "tumor": 1,
    "composition": 1,
    "recombinant": 1,
    "fusion": 1,
    "consisting": 1,
    "vegfbinding": 1,
    "portions": 1,
    "extracellular": 1,
    "domains": 1,
    "human": 3,
    "receptors": 1,
    "1": 1,
    "2": 1,
    "fused": 1,
    "fc": 1,
    "portion": 1,
    "igg1": 1,
    "immunoglobulin": 1,
    "history": 1,
    "commenced": 1,
    "clinical": 2,
    "testing": 2,
    "2001": 1,
    "2003": 1,
    "signed": 2,
    "major": 1,
    "deal": 1,
    "aventis": 1,
    "develop": 2,
    "field": 1,
    "2004": 1,
    "started": 1,
    "compound": 1,
    "locally": 2,
    "delivered": 1,
    "proliferative": 1,
    "diseases": 1,
    "2006": 1,
    "bayer": 1,
    "agreement": 1,
    "indications": 1,
    "society": 1,
    "culture": 1,
    "legal": 1,
    "status": 1,
    "november": 2,
    "2011": 4,
    "food": 1,
    "drug": 1,
    "administration": 1,
    "august": 5,
    "2012": 3,
    "use": 7,
    "5fluorouracil": 2,
    "folinic": 2,
    "acid": 2,
    "adults": 2,
    "oxaliplatin\u2011containing": 1,
    "avoid": 1,
    "confusion": 1,
    "version": 1,
    "injected": 1,
    "assigned": 1,
    "name": 1,
    "zivaflibercept": 3,
    "ingredient": 1,
    "european": 4,
    "medicines": 3,
    "agency": 3,
    "ema": 2,
    "2013": 1,
    "based": 1,
    "oxaliplatin": 1,
    "worked": 1,
    "got": 1,
    "worse": 1,
    "biosimilars": 1,
    "yesafili": 2,
    "union": 1,
    "september": 3,
    "2024": 6,
    "afliberceptjbvf": 1,
    "afliberceptyszy": 1,
    "opuviz": 3,
    "united": 4,
    "states": 4,
    "afliberceptmrbb": 1,
    "ahzantive": 1,
    "june": 1,
    "biosimilar": 5,
    "afliberceptabzv": 1,
    "enzeevu": 1,
    "afliberceptayyh": 1,
    "pavblu": 1,
    "committee": 1,
    "medicinal": 7,
    "products": 1,
    "chmp": 2,
    "adopted": 2,
    "positive": 2,
    "opinion": 2,
    "recommending": 2,
    "granting": 2,
    "marketing": 2,
    "authorization": 2,
    "product": 6,
    "intended": 2,
    "secondary": 3,
    "branch": 2,
    "rvo": 4,
    "central": 2,
    "dme": 2,
    "myopic": 4,
    "choroidal": 2,
    "neovascularization": 2,
    "cnv": 2,
    "applicant": 2,
    "samsung": 1,
    "bioepis": 1,
    "nl": 1,
    "bv": 1,
    "afqlir": 2,
    "sandoz": 1,
    "gmbh": 1,
    "economics": 1,
    "march": 2,
    "2015": 1,
    "one": 2,
    "group": 1,
    "delisted": 1,
    "uk": 1,
    "fund": 1,
    "2017": 2,
    "injections": 3,
    "hcpcs": 1,
    "code": 1,
    "j0178": 1,
    "responsible": 1,
    "billing": 1,
    "medicare": 1,
    "part": 1,
    "b": 1,
    "us236": 1,
    "billion": 1,
    "research": 1,
    "failed": 1,
    "primary": 2,
    "endpoint": 3,
    "overall": 2,
    "survival": 3,
    "vital": 1,
    "phase": 3,
    "iii": 3,
    "trial": 3,
    "secondline": 2,
    "advanced": 1,
    "nonsmall": 1,
    "lung": 1,
    "although": 1,
    "improved": 2,
    "progressionfree": 1,
    "april": 2,
    "velour": 1,
    "also": 1,
    "hormonerefractory": 1,
    "prostate": 1,
    "2016": 1,
    "cochrane": 1,
    "review": 2,
    "examined": 1,
    "outcomes": 3,
    "comparing": 1,
    "versus": 1,
    "ranibizumab": 2,
    "2400": 1,
    "amd": 1,
    "two": 1,
    "randomized": 1,
    "controlled": 1,
    "trials": 1,
    "options": 1,
    "yielded": 1,
    "similar": 1,
    "improvements": 1,
    "acuity": 1,
    "morphological": 1,
    "though": 1,
    "authors": 1,
    "note": 1,
    "potential": 1,
    "reduce": 1,
    "burden": 1,
    "risks": 1,
    "frequent": 1,
    "update": 1,
    "studying": 1,
    "antivegf": 1,
    "found": 1,
    "three": 1,
    "studied": 1,
    "treatments": 1,
    "advantages": 2,
    "laser": 1,
    "therapy": 1,
    "moderate": 1,
    "evidence": 1,
    "significantly": 1,
    "favored": 1,
    "measured": 1,
    "efficacy": 1,
    "bevacizumab": 1,
    "year": 1,
    "longer": 1,
    "term": 1,
    "unclear": 1,
    "references": 1,
    "external": 1,
    "links": 1,
    "medlineplus": 1,
    "national": 1,
    "institute": 1,
    "15": 1,
    "retrieved": 1,
    "10": 1
  },
  "title-length": 1,
  "content-length": 758,
  "curious_frequency": 1,
  "uplifting_frequency": 2,
  "entertaining_frequency": 1,
  "sad_frequency": 2,
  "general_frequency": 0
}